Last reviewed: June 19, 2026
Last updated: June 19, 2026
Written by:
Jay Hastings,
CEO of PlexusDx
Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.
Medically reviewed by:
Jayden Lee, PharmD, EMBA
Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.
This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.
Semaglutide, sold as Wegovy for weight loss, carries a pregnancy category rating that requires careful consideration for women planning to conceive or already pregnant. The FDA has not established safety in human pregnancy, and animal models have raised developmental concerns that warrant stopping the medication before attempting conception. Understanding these risks helps patients and providers make informed decisions about timing and alternatives.
FDA Pregnancy Category and Semaglutide Safety Data
Semaglutide falls into a category where human pregnancy data is limited or absent, prompting the manufacturer and FDA to recommend against use during pregnancy. Animal reproduction studies in rats and rabbits showed dose-dependent increases in fetal loss and skeletal abnormalities at exposures comparable to or lower than clinical doses. These findings do not prove harm in humans, but they signal enough uncertainty that medical guidelines advise caution and discontinuation before conception.
The lack of large-scale human trials means that safety cannot be confirmed through the gold standard of randomized controlled studies. Most pregnancy data for weight-loss medications come from case reports or small observational studies, which cannot rule out rare but serious complications. Because pregnancy itself carries metabolic demands and fetal development requires precise hormonal balance, the addition of a GLP-1 receptor agonist introduces an unquantified risk that most providers and patients choose to avoid.
How Semaglutide Works and Why Pregnancy Exposure Matters
Semaglutide mimics glucagon-like peptide-1 (GLP-1), a hormone that regulates blood sugar, appetite, and gastrointestinal function. The GLP-1 receptor is expressed in multiple fetal tissues, including the pancreas and intestines, meaning the drug could theoretically influence fetal metabolism and organ development. While the placenta may limit some drug passage to the fetus, semaglutide is a large peptide and transfer rates are not fully characterized, leaving a window of unknown fetal exposure.
During pregnancy, maternal blood sugar control directly affects fetal growth and development. Semaglutide lowers glucose and slows gastric emptying, changes that might seem beneficial but occur without the safety validation needed in this vulnerable population. The developing fetus relies on steady nutrient delivery and precise hormonal signals; introducing a medication that alters these signals without pregnancy-specific safety data creates unnecessary medical risk.
Clinical Recommendations: Stopping Semaglutide Before Pregnancy
Current clinical guidance from endocrinology societies recommends discontinuing semaglutide at least one menstrual cycle (approximately 4 weeks) before attempting conception. This washout period allows the medication to clear the body and hormone levels to normalize before implantation occurs. Women taking semaglutide who wish to become pregnant should schedule a preconception visit with their prescriber to plan the timing of drug discontinuation and discuss alternative weight management strategies.
If a patient becomes unexpectedly pregnant while on semaglutide, she should contact her prescriber immediately rather than stopping abruptly on her own. The healthcare provider can assess individual risk, review the timing and dose exposure, and determine whether additional monitoring or fetal assessment is warranted. Sudden discontinuation of any chronic medication during pregnancy also carries risks, making professional guidance essential.
Weight Management Strategies Before and After Pregnancy
Women planning pregnancy should discuss with their doctor when to stop semaglutide and which evidence-based alternatives might support healthy weight before conception. Structured nutrition counseling, supervised exercise, behavioral coaching, and medical nutrition therapy can all help achieve a stable, healthy weight without pharmacological GLP-1 support. PlexusDx Compounded Semaglutide Injection (starting at $149/month) is an option for women not planning pregnancy in the near term, but discontinuation timelines should be established with a provider.
During pregnancy and the postpartum period, weight management focuses on supporting maternal health and fetal development rather than active weight loss. After breastfeeding (if chosen) has concluded and the body has stabilized, women interested in resuming semaglutide for weight loss can restart with their provider's guidance, typically after the postpartum check-up. The Precision Peptide Genetic Test available from PlexusDx ($99 add-on after first month) can help personalize future therapy by identifying individual genetic pathways (including GLP1R rs6923761 and MC4R rs17782313 variants) that influence medication response and tolerability.
How Your Genetics Influence GLP-1 Response
Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month of treatment) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.
Access Personalized GLP-1 Care Through PlexusDx
PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection starts at $149/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.
Frequently Asked Questions
What should I do if I become pregnant while taking semaglutide?
Contact your prescriber immediately—do not stop the medication abruptly on your own. Your doctor will review your exposure timing, assess individual risk, and coordinate any necessary prenatal monitoring. Sudden medication withdrawal during pregnancy can also be unsafe, so professional guidance is essential.
How long should I wait after stopping semaglutide before trying to conceive?
Most clinical guidance recommends waiting at least one full menstrual cycle (approximately 4 weeks) after your last dose before attempting conception. This allows semaglutide to clear from your system and hormone levels to stabilize. Your prescriber can provide personalized timing based on your dose and medical history.
Are there any GLP-1 medications that are safe during pregnancy?
No GLP-1 receptor agonists currently carry FDA approval or safety designation for use in pregnancy. Semaglutide, tirzepatide, and all other agents in this class should be discontinued before conception. If you need blood sugar management during pregnancy due to diabetes, your doctor may recommend insulin or other pregnancy-approved agents instead.
Can I breastfeed after restarting semaglutide following pregnancy?
Very limited data exists on semaglutide transfer into breast milk. Most providers recommend waiting until breastfeeding is complete before restarting the medication. Discuss the pros and cons with your obstetrician and prescriber to weigh personal circumstances and feeding goals.
How can I plan pregnancy while managing my weight with PlexusDx?
Work with your PlexusDx prescriber to establish a preconception discontinuation date, typically one cycle before attempting conception. After delivery and completion of postpartum recovery, you can explore resuming semaglutide therapy; the Precision Peptide Genetic Test can then guide personalized dosing based on your GLP1R and other peptide-pathway variants for optimized outcomes.
Related Reading
Pricing and availability current as of June 2026. Compounded GLP-1 medications are not FDA-approved drug products; they are prepared by licensed compounding pharmacies under federal compounding regulations. Compounded semaglutide and tirzepatide are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting, stopping, or changing any medication.
Return to the PlexusDx Education Hub for more evidence-based resources on GLP-1 therapy, metabolic health, and personalized weight management.
Medical and Editorial Standards
Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.
Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.
Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.
Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.
Share:
When Are Zepbound Side Effects Worst?
Is Stomach Pain a Side Effect of Ozempic?